World-Class Biopharmaceutical Training for Academia and Industry - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

World-Class Biopharmaceutical Training for Academia and Industry

The driving motivation behind Ireland's National Institute for Bioprocessing Research and Training (NIBRT) is to help the development of the biopharmaceutical, by developing comprehensive research and training programs for both academic students and industry professionals. By ensuring the creation and sustainability of the biopharmaceutical workforce with superior skills and competencies, the promise of more effective biotherapeutic innovations addressing the world's most challenging diseases is becoming a reality.

NIBRT provides a “one stop shop” for thousands of trainees worldwide, and offers a dynamic catalogue of course content from which unique training solutions are built for clients. NIBRT delivers holistic training programs in a realistic GMP-simulated, fully operational manufacturing environment and cutting-edge analytical laboratory suite. All training programmes can be customized to meet a client’s particular requirements.

NIBRT Key Features:

  • Purpose-built, multifunctional facility replicating the most modern industrial bioprocessing environment
  • Pilot plant consisting of extensive upstream, downstream and fill-finish facilities
  • A complete bioanalytical laboratory for hands-on scientific training of 'fit-for-purpose' biopharmaceutical analysis, including protein and peptide characterization
  • Also offer extensive course content on existing and upcoming U.S. and European drug regulations.

Get the most comprehensive overviews of the concepts, strategies and techniques – on all aspects of bioprocessing. Book your course today.

info@nibrt.ie

http://www.nibrt.ie/cat_training_schedule.jsp

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FindPharma Custom Search

Click here